Dr. Adam Abodeely, MD, MBA Discusses Cannabinoids & Gastrointestinal Ailments at the April 5th Journal Club
Join us on Wednesday, April 5th at 9AM PT / 12PM ET as Dr. Adam Abodeely discusses his unpublished research on Cannabinoids and Gastrointestinal Ailments. Check out the the abstract below from his unpublished article “The minor cannabinoids and their potential implications for conditions of the gastrointestinal system”.
Abstract:
Previous data has shown that cannabis shows promise as an effective and alleviating medication for individuals with gastro- intestinal (GI) disorders and diseases. There has been discussion around THC and CBD’s beneficial impact for GI function as well as potential diseases, but there is no centralized data on other minor cannabinoids or acidic cannabinoids such as CBC, CBG, CBN, CBDV, THCA and CBDA. This study was designed to review several of these less discussed cannabinoids and how they might emerge as relevant therapeutic agents in the future. Keywords such as ”minor cannabinoids”, ”gastrointestinal system”, ‘‘gastrointestinal conditions”, and “cannabinoids” were entered in databases such as Google Scholar and Pub Med. The data collected was analyzed, treated and synthetized, according to the study’s objectives. 80 manuscripts were analyzed. Science has established a link between the endocannabinoid system and the roles it plays for a variety of GI functions including gut motility, immunity, secretion, and inflammation. Regarding exogenous cannabinoids, the effects on the gastrointestinal system are not limited to CBD and THC (extensively studied in the literature). Cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) also affect gastrointestinal tract or conditions. For example, in preclinical studies, CBC, CBDA, THCA and CBDV have demonstrated an ability to reduce intestinal inflammation making it a potential therapeutic agent for the treatment of inflammatory bowel disease and other forms of colitis. CBN has shown an ability to decrease GI motility and therefore might be studied in the future for diarrhea, constipation or other motility disorders. This data will be used to shape future studies to better define the role of cannabinoid therapy for a variety of gastrointestinal conditions.
REGISTER